Henry R Black

Summary

Publications

  1. doi Aliskiren alone or in combination with hydrochlorothiazide in Hispanic/Latino patients with systolic blood pressure 160 mm Hg to <180 mm Hg (aliskiren alone or in combination with hydrochlorothiazide in patients with stage 2 hypertension to provide qui
    Henry R Black
    Section of Cardiology, New York University Center for the Prevention of Cardiovascular Disease, New York University School of Medicine, New York, NY 10016, USA
    J Clin Hypertens (Greenwich) 14:514-21. 2012
  2. ncbi Secondary hypertension
    Henry R Black
    New York University Center for the Prevention of Cardiovascular Disease, New York University School of Medicine, New York, NY 10003, USA
    J Clin Hypertens (Greenwich) 10:520-1. 2008
  3. ncbi Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study
    Henry R Black
    New York University School of Medicine, New York, NY 10016, USA
    J Clin Hypertens (Greenwich) 9:760-9. 2007
  4. doi Valsartan: more than a decade of experience
    Henry R Black
    New York University Center for the Prevention of Cardiovascular Disease, New York University School of Medicine, New York, New York 10003, USA
    Drugs 69:2393-414. 2009
  5. doi Comparative efficacy and safety of combination aliskiren/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension
    Henry R Black
    New York University, New York, NY, USA
    J Clin Hypertens (Greenwich) 13:571-81. 2011
  6. doi Aliskiren alone or in combination with hydrochlorothiazide in patients with the lower ranges of stage 2 hypertension: The ACQUIRE randomized double-blind study
    Henry R Black
    New York University School of Medicine, New York, NY, USA
    J Clin Hypertens (Greenwich) 12:917-26. 2010
  7. doi The foundation role of beta blockers across the cardiovascular disease spectrum: a year 2009 update
    Henry R Black
    New York University Medical Center, New York, NY, USA
    Am J Med 123:S2. 2010
  8. ncbi Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent
    Henry R Black
    New York University School of Medicine, New York, New York, USA
    Diabetes Care 31:353-60. 2008
  9. doi Evidence for a lower target blood pressure for people with heart disease
    Clive Rosendorff
    Mount Sinai School of Medicine, New York, New York, USA
    Curr Opin Cardiol 24:318-24. 2009
  10. doi ASH position paper: treatment of hypertension in patients with diabetes-an update
    George L Bakris
    Hypertensive Diseases and Diabetes Center, Department of Medicine, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
    J Clin Hypertens (Greenwich) 10:707-13; discussion 714-5. 2008

Collaborators

Detail Information

Publications66

  1. doi Aliskiren alone or in combination with hydrochlorothiazide in Hispanic/Latino patients with systolic blood pressure 160 mm Hg to <180 mm Hg (aliskiren alone or in combination with hydrochlorothiazide in patients with stage 2 hypertension to provide qui
    Henry R Black
    Section of Cardiology, New York University Center for the Prevention of Cardiovascular Disease, New York University School of Medicine, New York, NY 10016, USA
    J Clin Hypertens (Greenwich) 14:514-21. 2012
    ..Aliskiren alone or in combination with HCT is safe and effective in Hispanic/Latino patients with stage 2 hypertension. Combination aliskiren/HCT produced greater blood pressure reductions than aliskiren monotherapy...
  2. ncbi Secondary hypertension
    Henry R Black
    New York University Center for the Prevention of Cardiovascular Disease, New York University School of Medicine, New York, NY 10003, USA
    J Clin Hypertens (Greenwich) 10:520-1. 2008
  3. ncbi Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study
    Henry R Black
    New York University School of Medicine, New York, NY 10016, USA
    J Clin Hypertens (Greenwich) 9:760-9. 2007
    ....
  4. doi Valsartan: more than a decade of experience
    Henry R Black
    New York University Center for the Prevention of Cardiovascular Disease, New York University School of Medicine, New York, New York 10003, USA
    Drugs 69:2393-414. 2009
    ..The combination of valsartan/HCTZ was better tolerated than HCTZ alone. Valsartan is administered once daily for hypertension; doses are usually taken upon awakening. In patients with HF or MI, valsartan is administered twice daily...
  5. doi Comparative efficacy and safety of combination aliskiren/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension
    Henry R Black
    New York University, New York, NY, USA
    J Clin Hypertens (Greenwich) 13:571-81. 2011
    ..The combination of aliskiren/amlodipine reduced peripheral, ambulatory, and central BP more than amlodipine alone with similar tolerability in African Americans with stage 2 hypertension...
  6. doi Aliskiren alone or in combination with hydrochlorothiazide in patients with the lower ranges of stage 2 hypertension: The ACQUIRE randomized double-blind study
    Henry R Black
    New York University School of Medicine, New York, NY, USA
    J Clin Hypertens (Greenwich) 12:917-26. 2010
    ..Aliskiren, with or without HCT, provides clinically significant BP reductions and may therefore be an effective treatment option in patients with stage 2 hypertension...
  7. doi The foundation role of beta blockers across the cardiovascular disease spectrum: a year 2009 update
    Henry R Black
    New York University Medical Center, New York, NY, USA
    Am J Med 123:S2. 2010
    ..Their beneficial abilities include improvement of oxygen supply and demand (which can reduce myocardial ischemia), anti-arrhythmic properties, and beneficial effects on cardiac remodeling...
  8. ncbi Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent
    Henry R Black
    New York University School of Medicine, New York, New York, USA
    Diabetes Care 31:353-60. 2008
    ..Optimal initial antihypertensive drug therapy in people with the metabolic syndrome is unknown...
  9. doi Evidence for a lower target blood pressure for people with heart disease
    Clive Rosendorff
    Mount Sinai School of Medicine, New York, New York, USA
    Curr Opin Cardiol 24:318-24. 2009
    ..The review assesses the evidence for the benefit of lower blood pressure (BP) targets in hypertension management...
  10. doi ASH position paper: treatment of hypertension in patients with diabetes-an update
    George L Bakris
    Hypertensive Diseases and Diabetes Center, Department of Medicine, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
    J Clin Hypertens (Greenwich) 10:707-13; discussion 714-5. 2008
    ..Last, an updated algorithm is provided that incorporates many of the new findings and is suggested as a starting point to achieve blood pressure goals...
  11. doi Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial
    George L Bakris
    University of Chicago, Department of Medicine, Hypertensive Disease Unit, Chicago, Ill, USA
    Hypertension 56:824-30. 2010
    ..The results of this trial highlight the importance of ambulatory BP monitoring in the design of hypertension clinical studies...
  12. ncbi Commentary on ICEBERG
    Henry R Black
    New York University School of Medicine, New York, NY 10003, USA
    J Clin Hypertens (Greenwich) 9:557. 2007
  13. ncbi American Society of Hypertension, Inc.: president's message
    Henry R Black
    Clinical Professor of Internal Medicine, NYU Center for Prevention of Cardiovascular Disease, New York, USA
    J Clin Hypertens (Greenwich) 10:417. 2008
  14. doi Association of Clinical Researchers and Educators a statement on relationships between physicians and industry
    Michael A Weber
    State University of New York, Downstate College of Medicine, Brooklyn, New York, 112013, USA
    Endocr Pract 18:1029-37. 2012
    ....
  15. ncbi When and how to use self (home) and ambulatory blood pressure monitoring
    Thomas G Pickering
    Center for Behavioral Cardiovascular Health, Columbia Presbyterian Medical Center, New York, NY, USA
    J Am Soc Hypertens 4:56-61. 2010
    ....
  16. ncbi Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial
    Frans H H Leenen
    University of Ottawa Heart Institute, Ottawa, Ontario, Canada
    Hypertension 48:374-84. 2006
    ..Some, but not all, of these differences may be explained by less effective blood pressure control in the lisinopril arm...
  17. ncbi The cardiometabolic syndrome and calcium channel blocker combination drugs
    James R Sowers
    Diabetes Research Center, University of Missouri Columbia, Columbia, MO, USA
    J Cardiometab Syndr 2:207-12. 2007
    ..The authors maintained full control of the discussion and the resulting content of this article...
  18. ncbi Controlled-release doxazosin as combination therapy in hypertension: the GATES study
    Henry R Black
    Rush Presbyterian St Luke s Medical Center, Chicago, IL 60612, USA
    J Clin Hypertens (Greenwich) 8:159-66; quiz 167-8. 2006
    ..0%), the frequency of adverse events was similar for doxazosin GITS and placebo. Doxazosin GITS was effective as combination antihypertensive therapy with the major classes of antihypertensive agents...
  19. ncbi The role of therapeutic inertia and the use of fixed-dose combination therapy in the management of hypertension
    Jan Basile
    Ralph H Johnson VA Medical Center, Charleston, SC, USA
    J Clin Hypertens (Greenwich) 9:636-45. 2007
  20. ncbi Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    Linda B Piller
    University of Texas Health Science Center at Houston, School of Public Health, Houston, TX 77030, USA
    J Clin Hypertens (Greenwich) 8:649-56; quiz 657-8. 2006
    ..One patient died following an angioedema episode. The occurrence of angioedema in the angiotensin-converting enzyme inhibitor arm corresponds with previously reported angioedema-angiotensin-converting enzyme inhibitor associations...
  21. ncbi Feasibility of treating prehypertension with an angiotensin-receptor blocker
    Stevo Julius
    University of Michigan, Department of Internal Medicine, Division of Cardiovascular Medicine, Ann Arbor, MI 48106, USA
    N Engl J Med 354:1685-97. 2006
    ..Prehypertension is considered a precursor of stage 1 hypertension and a predictor of excessive cardiovascular risk. We investigated whether pharmacologic treatment of prehypertension prevents or postpones stage 1 hypertension...
  22. ncbi The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis
    Paula T Einhorn
    National Heart, Lung, and Blood Institute, Division of Epidemiology and Clinical Applications, Bethesda, MD 20892 7936, USA
    Am Heart J 153:42-53. 2007
    ..However, questions have been raised regarding the validity of the HF diagnosis...
  23. ncbi Blood pressure reduction is not the only determinant of outcome
    Peter S Sever
    International Centre for Circulatory Health, Imperial College London, 59 N Wharf Rd, London, W2 1PG, UK
    Circulation 113:2754-72; discussion 2773-4. 2006
  24. ncbi The editor's roundtable: revisiting the role of beta blockers in hypertension
    William C Roberts
    Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Texas, USA
    Am J Cardiol 100:253-67. 2007
  25. ncbi Resistant hypertension revisited: a comparison of two university-based cohorts
    Jay P Garg
    Department of Preventive Medicine, Rush University Medical Center, Chicago, Illinois, 60612, USA
    Am J Hypertens 18:619-26. 2005
    ..To assess whether the reasons for and treatment of RH have changed, we determined the frequency of various causes of resistance, the proportion of patients achieving goal BP, and the changes made in antihypertensive regimens...
  26. pmc Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    Jackson T Wright
    Department of Medicine, General Clinical Research Center, Cleveland, Ohio, USA
    Arch Intern Med 168:207-17. 2008
    ....
  27. ncbi Goal-oriented hypertension management: translating clinical trials to practice
    Gregory M Singer
    Rush University Hypertension Service, Rush Presbyterian St Luke s Medical Center, Chicago, Ill 60612, USA
    Hypertension 40:464-9. 2002
    ..Although DBP control was easy to achieve, achieving SBP goal still remained difficult. Employing goal-oriented management can translate BP control results achieved in clinical trials into outpatient practice...
  28. ncbi Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
    William C Cushman
    J Clin Hypertens (Greenwich) 4:393-404. 2002
    ..Achievable control rates in varied practice settings and geographic regions and factors that predict improved blood pressure control are not well identified...
  29. ncbi Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial
    Henry R Black
    Rush Medical College of Rush University, Chicago, IL 60612, USA
    JAMA 289:2073-82. 2003
    ..Hypertensive patients are often given a calcium antagonist to reduce cardiovascular disease risk, but the benefit compared with other drug classes is controversial...
  30. ncbi The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report
    Aram V Chobanian
    Department of Medicine, Boston University School of Medicine, Boston, Mass, USA
    JAMA 289:2560-72. 2003
    ..Empathy builds trust and is a potent motivator. Finally, in presenting these guidelines, the committee recognizes that the responsible physician's judgment remains paramount...
  31. ncbi Doxazosin as combination therapy for patients with stage 1 and stage 2 hypertension
    Henry R Black
    Rush Presbyterian St Luke s Medical Center, 1700 W Van Buren St, Suite 470, Chicago, IL 60612 3824, USA
    J Cardiovasc Pharmacol 41:866-9. 2003
    ..The positive effects of doxazosin on serum lipids make combination therapy with doxazosin an attractive treatment option for patients who have concomitant hyperlipidemia or glucose intolerance...
  32. ncbi Evolving role of aldosterone blockers alone and in combination with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in hypertension management: a review of mechanistic and clinical data
    Henry R Black
    Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, Chicago, IL 60612, USA
    Am Heart J 147:564-72. 2004
    ..This article reviews the role of the RAAS in the development of hypertension and discusses the rationale for the use of eplerenone with other medications affecting the RAAS to control blood pressure...
  33. ncbi Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial
    John B Kostis
    Department of Medicine, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, One Robert Wood Johnson Place, PO Box 19, New Brunswick, NJ 08903 0019, USA
    Am J Hypertens 17:103-11. 2004
    ..We compared the efficacy and safety of omapatrilat to a representative angiotensin-converting enzyme (ACE) inhibitor, enalapril...
  34. ncbi Hypertension in women: the Women Take Heart project
    A lice A Furumoto-Dawson
    Department of Preventive Medicine, Rush Medical College, Rush Presbyterian St Lukes Medical Center, Chicago, IL 60612, USA
    J Clin Hypertens (Greenwich) 5:38-46. 2003
    ..1% of self-reported hypertensives. Results from this study and national surveys indicate that hypertension detection and control remain major public health challenges in preventing cardiovascular disease in older women...
  35. pmc Effect of calcium and vitamin D supplementation on blood pressure: the Women's Health Initiative Randomized Trial
    Karen L Margolis
    HealthPartners Research Foundation, Box 1524, Mailstop 21111R, Minneapolis, Minnesota 55440 1524, USA
    Hypertension 52:847-55. 2008
    ..01 (95% CI: 0.96 to 1.06.) In postmenopausal women, calcium plus vitamin D3 supplementation did not reduce either blood pressure or the risk of developing hypertension over 7 years of follow-up...
  36. ncbi Pharmacologic considerations in the positioning of beta-blockers in antihypertensive therapy
    Domenic A Sica
    Clinical Pharmacology and Hypertension, Virginia Commonwealth University Health System, Richmond, VA 23298, USA
    Curr Hypertens Rep 10:330-5. 2008
    ..The most recently introduced drugs, the vasodilating beta-blockers carvedilol and nebivolol, are now being broadly evaluated as to their efficacy and tolerability in clinical practice...
  37. ncbi Prehypertension
    William J Elliott
    Department of Preventive Medicine, Rush Medical College, Rush University Medical Center, Chicago, IL 60612, USA
    Nat Clin Pract Cardiovasc Med 4:538-48. 2007
    ..In this Review, we attempt to summarize the recently published data concerning the epidemiology, attendant risks and potential treatment options for this important and growing public-health problem...
  38. ncbi Microalbuminuria, chronic renal disease, and the effects of the metabolic syndrome on cardiovascular events
    Marvin Moser
    J Clin Hypertens (Greenwich) 9:551-6. 2007
    ..The authors maintained full control of the discussion and the resulting content of this article; Novartis had no input in the choice of topic, speakers, or content...
  39. ncbi Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Preventi
    Clive Rosendorff
    Veterans Health Administration, USA
    Circulation 115:2761-88. 2007
  40. ncbi Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 49:1982-8. 2007
    ..The purpose of this study was to determine the possible benefit of dual antiplatelet therapy in patients with prior myocardial infarction (MI), ischemic stroke, or symptomatic peripheral arterial disease (PAD)...
  41. ncbi Prehypertension and cardiovascular disease risk in the Women's Health Initiative
    Judith Hsia
    Department of Medicine, George Washington University, 2150 Pennsylvania Ave NW, Washington, DC 20037, USA
    Circulation 115:855-60. 2007
    ..Prehypertension is common and is associated with increased vascular mortality. The extent to which it increases risk of nonfatal myocardial infarction, stroke, and congestive heart failure is less clear...
  42. ncbi A comparison of two sphygmomanometers that may replace the traditional mercury column in the healthcare workplace
    William J Elliott
    Department of Preventive Medicine, Rush Medical College, Chicago, IL 60612, USA
    Blood Press Monit 12:23-8. 2007
    ....
  43. ncbi Guidelines for hypertension: are quality-assurance measures on target?
    Gregory M Singer
    Rush University Hypertension Service, Chicago, Ill, USA
    Hypertension 43:198-202. 2004
    ..Goal-oriented strategy, especially in diabetic subjects, should be aggressively sought rather than relaxing goals to promote achievement...
  44. ncbi Treatment of hypertension in the elderly
    Warren J Elliott
    Department of Preventive Medicine, RUSH Medical College of RUSH University at RUSH Presbyterian St Luke s Medical Center, 1700 West Van Buren Street, Chicago, IL 60612, USA
    Am J Geriatr Cardiol 11:11-20; quiz 20-2. 2002
    ..Future cardiovascular risk may be related directly to the blood pressure attained, rather than to how it was attained...
  45. ncbi Management of older hypertensive patients: is there a difference in approach?
    Henry R Black
    Rush University Medical Center, Chicago, IL 60612, USA
    J Clin Hypertens (Greenwich) 5:11-6. 2003
    ..No older person should suffer a preventable, life-threatening event or become confined to a wheel chair if attention to lifestyle issues and a few pills a day could avoid that outcome...
  46. ncbi Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
    Aram V Chobanian
    Boston University School of Medicine, Boston, Mass, USA
    Hypertension 42:1206-52. 2003
    ..Positive experiences, trust in the clinician, and empathy improve patient motivation and satisfaction. This report serves as a guide, and the committee continues to recognize that the responsible physician's judgment remains paramount...
  47. ncbi The burden of cardiovascular disease: following the link from hypertension to myocardial infarction and heart failure
    Henry R Black
    Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, 1700 West Van Buren, Suite 470, Chicago, IL 60612, USA
    Am J Hypertens 16:4S-6S. 2003
    ..Aggressive lowering of BP is critical to help reduce the risk of CVD and help prevent the development of HF...
  48. ncbi Estrogen plus progestin and the risk of coronary heart disease
    JoAnn E Manson
    Division of Preventive Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02215, USA
    N Engl J Med 349:523-34. 2003
    ..In this report, we provide the final results with regard to estrogen plus progestin and CHD from the Women's Health Initiative (WHI)...
  49. ncbi Angioedema in heart failure: occurrence with ACE inhibitors and safety of angiotensin receptor blocker therapy
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    Congest Heart Fail 8:334-41, 345. 2002
    ..The need to reduce renin-angiotensin aldosterone system activity in a heart failure patient would seem to justify the small risk of angioedema with ARB therapy in a patient having previously experienced ACE inhibitor-related angioedema...
  50. ncbi Chrono: a community-based hypertension trial of a chronotherapeutic formulation of verapamil
    L Michael Prisant
    Hypertension and Clinical Pharmacology, Medical College of Georgia, Augusta, GA 30912 3105, USA
    Am J Ther 9:476-83. 2002
    ..Upward titration of Verelan PM from 200 to 400 mg nearly doubled the DBP response rate (45.8% to 85.3%). This chronotherapeutic formulation of verapamil was well tolerated in this community trial...
  51. ncbi Current concepts of pharmacotherapy in hypertension: ACE inhibitor-related angioedema: can angiotensin-receptor blockers be safely used?
    Domenic A Sica
    Department of Medicine, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298, USA
    J Clin Hypertens (Greenwich) 4:375-80. 2002
    ..Such justification might include the presence of heart failure or proteinuric nephropathic states among other considerations...
  52. ncbi Risk stratification of older patients
    Henry R Black
    Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, Chicago, Illinois 60612, USA
    Am J Hypertens 15:77S-81S. 2002
    ..Otherwise, a multidrug regimen is constructed and additional agents added in logical fashion. A majority of patients with higher risk can attain control at the specified BP goal safely and effectively by using a combination of agents...
  53. ncbi Treatment of elderly hypertensive patients with a delayed-release verapamil formulation in a community-based trial
    Michael A Weber
    State University of New York Downstate College of Medicine, Brooklyn, NY 11203, USA
    Am J Geriatr Cardiol 13:131-6. 2004
    ..CODAS verapamil was found to be efficacious and well tolerated among elderly hypertensive patients in this community trial...
  54. ncbi Graded blood pressure reduction in hypertensive outpatients associated with use of a device to assist with slow breathing
    William J Elliot
    Department of Preventive Medicine, Rush Medical College of Rush University, Rush University Medical Center, Chicago, IL 60612, USA
    J Clin Hypertens (Greenwich) 6:553-9; quiz 560-1. 2004
    ....
  55. pmc Chronotherapeutic oral drug absorption system verapamil is effective in reducing morning blood pressure in African Americans: a post hoc analysis of the chrono trial
    L Michael Prisant
    Medical College of Georgia, Augusta, GA, USA
    J Natl Med Assoc 97:377-83. 2005
    ..In a trial conducted in actual clinical practices, the CODAS formulation of verapamil was shown to be safe and effective in African Americans, Caucasians, Hispanics and Asians...
  56. ncbi Improving blood pressure control rates: is there more we can do?
    George L Bakris
    Hypertension Center, Endocrine Division, The University of Chicago School of Medicine, Chicago, IL, USA
    J Clin Hypertens (Greenwich) 9:134-42. 2007
  57. ncbi Prehypertension--what is it and should it be treated?
    Marvin Moser
    J Clin Hypertens (Greenwich) 8:812-8. 2006
  58. ncbi Expanding the definition of hypertension to incorporate global cardiovascular risk
    Nitin Khosla
    Rush University Hypertension Center, Rush Presbyterian St Luke s Medical Center, 1700 W Van Buren Street, Suite 470, Chicago, IL 60612, USA
    Curr Hypertens Rep 8:384-90. 2006
    ..To change this alarming trend, physicians must become aggressive in using the available armamentarium of lifestyle modifications and drugs in treating hypertension and other risk factors that increase the burden of atherosclerosis...
  59. ncbi Expanding the definition and classification of hypertension
    Thomas D Giles
    Louisiana State University School of Medicine, New Orleans, LA 70112, USA
    J Clin Hypertens (Greenwich) 7:505-12. 2005
    ..We believe it would be preferable to classify all individuals as either normal or hypertensive, based on their cardiovascular evaluation, using the four categories of normal and stages 1, 2, and 3 hypertension...
  60. ncbi Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events
    Deepak L Bhatt
    Cleveland Clinic, Cleveland, USA
    N Engl J Med 354:1706-17. 2006
    ..Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been studied in a broad population of patients at high risk for atherothrombotic events...
  61. ncbi Calcium plus vitamin D supplementation and the risk of colorectal cancer
    Jean Wactawski-Wende
    Department of Social and Preventive Medicine, University at Buffalo, 270 Farber Hall, Buffalo, NY 14214, USA
    N Engl J Med 354:684-96. 2006
    ..However, randomized-trial evidence that calcium with vitamin D supplementation is beneficial in the primary prevention of colorectal cancer is lacking...
  62. ncbi Calcium plus vitamin D supplementation and the risk of fractures
    Rebecca D Jackson
    Division of Endocrinology, Ohio State University, 485 McCampbell, 1581 Dodd Dr, Columbus, OH 43210, USA
    N Engl J Med 354:669-83. 2006
    ..The efficacy of calcium with vitamin D supplementation for preventing hip and other fractures in healthy postmenopausal women remains equivocal...
  63. ncbi ACE inhibitors: over two decades of use
    Domenic A Sica
    Virginia Commonwealth University, Richmond, VA, USA
    J Clin Hypertens (Greenwich) 7:531-7. 2005
    ..Dr. Henry R. Black of Rush University Medical Center, Chicago, IL; and Dr. Vito M. Campese of the University of Southern California, Los Angeles, CA...
  64. ncbi Calcium channel blockers in the treatment of hypertension and prevention of cardiovascular disease: results from major clinical trials
    Henry R Black
    Department of Preventive Medicine, Rush University Medical Center, Chicago, Illinois 60612, USA
    Clin Cornerstone 6:53-66. 2004
    ....
  65. ncbi Results of the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial by geographical region
    Henry R Black
    Department of Preventive Medicine, Rush University Medical Center, Chicago, Illinois 60612, USA
    J Hypertens 23:1099-106. 2005
    ..To examine regional differences in the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial...
  66. ncbi Design of the Omapatrilat in Persons with Enhanced Risk of Atherosclerotic events (OPERA) trial
    John B Kostis
    University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick 08903 0019, USA
    Am J Hypertens 15:193-8. 2002
    ..Additional analyses will be conducted in men and women, in diabetic patients, in different risk classes and according to prior evidence of vascular disease...